Big Pharma Buys Growth; Novartis Bets on Pipeline
Big Pharma is aggressively pursuing M&A to offset revenue losses from patent expiries, with biotech deal values reaching a record $216 billion in 2026. Meanwhile, Novartis (NVS) is betting on its internal pipeline rather than large acquisitions.
Key Numbers
The pharmaceutical industry is undergoing a strategic shift in 2026, with major companies turning to mergers and acquisitions (M&A) to compensate for revenues lost to the patent cliff. According to a report from Insider Monkey, biotech M&A has hit a record pace this year, with deal value reaching $216 billion so far.
Details
Big Pharma companies are acquiring small and mid-sized biotech firms to gain access to promising drugs in late-stage development, helping to fill revenue gaps as patents on their blockbuster drugs expire. This trend has led to an unprecedented acceleration in sector deals.
In contrast, Novartis (NYSE: NVS) is pursuing a different strategy, focusing on internal drug development through its pipeline rather than relying on large acquisitions. The company believes that internal innovation can provide more sustainable long-term growth.
Context
The patent cliff is a major challenge for pharmaceutical companies, as they lose exclusivity on profitable drugs and face competition from generics. In recent years, the sector has seen several large deals, such as Pfizer's (NYSE: PFE) acquisition of Seagen and Merck's (NYSE: MRK) acquisition of Acceleron.
What This Means for Investors
For investors, this trend offers an opportunity to evaluate different company strategies. Companies pursuing M&A may achieve rapid revenue growth but face integration risks and high valuations. In contrast, internal development strategies like Novartis' may offer more stable growth, though they require longer timelines to generate returns.
Frequently Asked Questions
Found this useful? Share it